Skip to content

Study · Randomized controlled trial · n = 39 · 2019

6 results

Oxytocin increases eye gaze in schizophrenia.

Bradley ER, Seitz A, Niles AN, Rankin KP, Mathalon DH, O'Donovan A, Woolley JD

Schizophrenia research12 Aug 2019Cited by 18 (Europe PMC)

PMID31416746 (opens in a new tab)PMCIDPMC6791758 (opens in a new tab)DOI10.1016/j.schres.2019.07.039 (opens in a new tab)PepBankPUB-31416746
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In neurotypical men, intranasal oxytocin decreased fixation time on the eyes of faces compared with placebo.

    In plain wordsIn men without schizophrenia, nasal oxytocin decreased the time they looked at the eyes of faces, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseFixation time on the eyes in neurotypical controls
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    40 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Oxytocin was associated with an increase in fixation time among patients, but a decrease among controls.
    1 context sentence
    Summary · context
    In a randomized, double-blind, crossover study, 33 men with schizophrenia and 39 matched controls received one dose of intranasal oxytocin (40 IU) and placebo on separate testing days.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with schizophrenia, intranasal oxytocin increased fixation time on the eyes of faces compared with placebo.

    In plain wordsIn men with schizophrenia, nasal oxytocin increased the time they looked at the eyes of faces, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseFixation time on the eyes in men with schizophrenia
    Study

    n = 33

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    40 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Oxytocin was associated with an increase in fixation time among patients, but a decrease among controls.
    1 context sentence
    Summary · context
    In a randomized, double-blind, crossover study, 33 men with schizophrenia and 39 matched controls received one dose of intranasal oxytocin (40 IU) and placebo on separate testing days.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with schizophrenia and controls, higher attachment anxiety predicted increased fixation time on the eyes with oxytocin versus placebo.

    In plain wordsIn men with schizophrenia and controls, higher attachment anxiety was linked to a larger rise in eye-looking time with oxytocin than with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseModeration of oxytocin effect on eye fixation by attachment anxiety
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    40 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Higher attachment anxiety and greater symptom severity predicted increased fixation time on the eyes on oxytocin versus placebo.
    1 context sentence
    Summary · context
    In a randomized, double-blind, crossover study, 33 men with schizophrenia and 39 matched controls received one dose of intranasal oxytocin (40 IU) and placebo on separate testing days.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In men with schizophrenia and controls, greater symptom severity predicted increased fixation time on the eyes with oxytocin versus placebo.

    In plain wordsIn men with schizophrenia and controls, greater symptom severity was linked to a larger rise in eye-looking time with oxytocin than with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseModeration of oxytocin effect on eye fixation by symptom severity
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    40 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Higher attachment anxiety and greater symptom severity predicted increased fixation time on the eyes on oxytocin versus placebo.
    1 context sentence
    Summary · context
    In a randomized, double-blind, crossover study, 33 men with schizophrenia and 39 matched controls received one dose of intranasal oxytocin (40 IU) and placebo on separate testing days.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In men with schizophrenia and controls, anti-dopaminergic medication dosage did not impact the response to oxytocin.

    In plain wordsIn men with schizophrenia and controls, the dose of anti-dopaminergic medicine did not change how they responded to oxytocin.

    Peptide
    Oxytocin
    Outcome
    No significant changeModeration by anti-dopaminergic medication dosage
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    40 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Anti-dopaminergic medication dosage and attachment avoidance did not impact response to oxytocin.
    1 context sentence
    Summary · context
    In a randomized, double-blind, crossover study, 33 men with schizophrenia and 39 matched controls received one dose of intranasal oxytocin (40 IU) and placebo on separate testing days.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In men with schizophrenia and controls, attachment avoidance did not impact the response to oxytocin.

    In plain wordsIn men with schizophrenia and controls, attachment avoidance did not change how they responded to oxytocin.

    Peptide
    Oxytocin
    Outcome
    No significant changeModeration by attachment avoidance
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    40 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    Anti-dopaminergic medication dosage and attachment avoidance did not impact response to oxytocin.
    1 context sentence
    Summary · context
    In a randomized, double-blind, crossover study, 33 men with schizophrenia and 39 matched controls received one dose of intranasal oxytocin (40 IU) and placebo on separate testing days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.